Navigation Links
MannKind Announces Positive Results from a Phase 1a Study of a GLP-1 Formulation
Date:11/5/2007

VALENCIA, Calif., Nov. 5 /PRNewswire-FirstCall/ -- MannKind Corporation (Nasdaq: MNKD) today announced results from a Phase 1a clinical evaluation of MKC253, a formulation of GLP-1 (glucagon-like peptide) on Technosphere particles that is delivered using the Company's proprietary inhaler. The study was designed as an open-label, dose escalation, controlled safety and tolerability trial, involving 26 healthy, adult, male subjects. Each subject was assigned to one of five dose levels of MKC253 inhalation powder: 0.05 mg, 0.45 mg, 0.75 mg, 1.05 mg or 1.5 mg.

The primary objective of the trial was to evaluate the tolerability of ascending doses of the investigational product as determined by the incidence and severity of reported adverse events. Secondary endpoints included pharmacokinetic parameters of plasma GLP-1 and pharmacodynamic parameters of plasma insulin and glucose.

GLP-1 plasma concentrations peaked very quickly, with a mean Tmax occurring less than 3 minutes after inhalation. In the group that received 1.5 mg of MKC253, the mean Cmax of total GLP-1 was 507 pmol/L, with active GLP-1 reaching a Cmax of 310 pmol/L. At all dose levels, MKC253 was well tolerated. Even in subjects that achieved plasma GLP-1 concentrations in excess of 100 pmol/L, the nausea and vomiting characteristically associated with such levels was not observed.

In these healthy subjects, GLP-1-induced insulin release occurred within 6 minutes of inhalation of MKC253. The insulin response was dose-dependent. The release of insulin from the pancreas was confirmed by corresponding significant increases in the levels of C-peptide. In subjects that received 1.5 mg of MKC253, blood glucose concentrations were observed to decrease
'/>"/>

SOURCE MannKind Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. MannKind to Present at the UBS Global Life Sciences Conference
2. MannKind Corporation Raises $250 Million in Self Managed Registered Direct Offerings of Common Stock
3. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
4. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
5. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
6. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
7. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
8. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
9. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
10. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
11. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... electrons, but one of the most promising technologies for ... on light (photons) instead of electrons. First, it is ... single photons and control their direction. Researchers around the ... this control, but now scientists at the Niels Bohr ... photons emitted one at a time and in a ...
(Date:8/29/2014)... 2014 The global companion diagnostics ... 2019. It is expected to grow at a ... was valued at $1.8 billion in 2013, according ... Research. , For more information regarding analysis details ... The research report, titled “Companion Diagnostics Market (Breast ...
(Date:8/29/2014)... New York (PRWEB) August 29, 2014 According ... “Global Orthobiologics Market” the global orthobiologics market was valued at ... a market worth USD 5,519.9million in 2019at a CAGR of ... population aged 50 years and above is afflicted by bone ... double by the year 2020. This has and will continue ...
(Date:8/29/2014)... (PRWEB) August 29, 2014 Pittcon is ... MacDonald, and colleague Koichiro Matsuda, Horiba Scientific, have organized ... September 5, 2014. JASIS , Asia’s largest analytical ... 2014, in Makuhari Messe, Japan. , The four ... for Bioanalysis from Single Molecules to Single Cells” will ...
Breaking Biology Technology:Breakthrough in light sources for new quantum technology 2Companion Diagnostics Market to Hit $5.6 Billion in 2019: Transparency Market Research 2Companion Diagnostics Market to Hit $5.6 Billion in 2019: Transparency Market Research 3Global Orthobiologics Market to Reach $5,519.9 Million by 2019: Transparency Market Research 2Global Orthobiologics Market to Reach $5,519.9 Million by 2019: Transparency Market Research 3Fifth Annual U.S. Symposium at JASIS Organized by Pittcon’s Program Chairman Hub MacDonald 2
... Biotech Products, L.P. today announced that data related to ... Society of Clinical Oncology (ASCO) Annual Meeting in Orlando, ... The studies were sponsored by Centocor Ortho Biotech Products, ... and Development, a unit of Johnson & Johnson Pharmaceutical ...
... 28 Plexus Corp. (Nasdaq: PLXS ) announced ... generation automated screening system for the pre-processing of human papillomavirus ... solution to a current manual process, through sophisticated robotic motions. ... for HPV; a virus that has an established link to ...
... Next step toward deploying biometric exit procedures for ... of Homeland Security (DHS) today began collecting biometrics ... citizens departing the United States as part of ... and Detroit Metropolitan Wayne County Airport. Since 2004, ...
Cached Biology Technology:Centocor Ortho Biotech Data to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting 2Centocor Ortho Biotech Data to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting 3Centocor Ortho Biotech Data to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting 4Centocor Ortho Biotech Data to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting 5Centocor Ortho Biotech Data to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting 6Centocor Ortho Biotech Data to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting 7Centocor Ortho Biotech Data to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting 8Centocor Ortho Biotech Data to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting 9Centocor Ortho Biotech Data to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting 10Centocor Ortho Biotech Data to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting 11Plexus Awarded Development Contract With QIAGEN 2Plexus Awarded Development Contract With QIAGEN 3Plexus Awarded Development Contract With QIAGEN 4DHS Begins Test of Biometric Exit Procedures at Two U.S. Airports 2
(Date:8/29/2014)... Ebola researcher from the University of Texas Medical Branch at ... three monoclonal antibodies can completely protect monkeys against a lethal ... at a time when the disease is severe. , Thomas ... for Nature discussing advances in Ebola treatment research. ... among the most deadly of pathogens, with fatality rates of ...
(Date:8/29/2014)... understand how the repeated climatic shifts over the ... of genetic diversity, a team of researchers led ... Ana Carnaval developed a new biodiversity metric called ... which the genetic variation within species is restricted ... professor of biology, and 14 other researchers from ...
(Date:8/29/2014)... type and number of connections in transcription factor networks ... in a study published in PLOS Computational Biology ... assortativity signature contributes to a network,s resilience against mutations. ... out-out assortativity of TFN models has a greater effect ... types of assortativity," said Dov A. Pechenick, PhD, lead ...
Breaking Biology News(10 mins):Leading Ebola researcher at UTMB says there's an effective treatment for Ebola 2CCNY team defines new biodiversity metric 2Assortativity signatures of transcription factor networks contribute to robustness 2
... has provided the first conclusive evidence that neurodevelopmental ... such as Alzheimer's disease, Parkinson's disease and ataxias ... specific gene defects that interfere with the electrical ... neurons. , The implicated gene, KCNC3, and two ...
... evolution of Earth's first animals will have to be ... according to a new study by Indiana University Bloomington ... of the National Academy of Sciences. , Purported ... last 12 years, mainly by paleontologists working in China. ...
... not only make teens more aggressive, but may keep ... ultimately wears off but there may be other, lasting ... in February's Behavioral Neuroscience, also showed that aggression rose ... the brain's aggression control region. Behavioral Neuroscience is ...
Cached Biology News:Study ties 'new' cell-death mechanism to developmental and degenerative brain disorders 2Study ties 'new' cell-death mechanism to developmental and degenerative brain disorders 3Embryos tell story of Earth's earliest animals 2Embryos tell story of Earth's earliest animals 3Animal models show that anabolic steroids flip the adolescent brain's switch for aggression 2Animal models show that anabolic steroids flip the adolescent brain's switch for aggression 3
... which can immunocapture up to 50 g ... included are 2 mg of bovine heart ... immunocapture kit allows isolation of the ATP ... of tissue. This facilitates subsequent analysis of ...
ASCIZ...
Anti-Flavocytochrome b Monoclonal, FITC Labeled Research Focus: other Storage: 4C Shipping Temperature: 4C...
Chaps Cell Extract Buffer can be used to lyse cells under nondenaturing conditions and is recommendedfor the preparation of cell lysates to be used with our caspase signaling pathway antibodies...
Biology Products: